Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Kufa, Tendesayi ^a,b   Mabuto, Tonderai ^a   Muchiri, Evans ^a   Charalambous, Salome ^a,b   Rosillon, Dominique ^c   Churchyard, Gavin ^a,b   Harris, Rebecca C ^c  

^a AURUM INSTITUTE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c GSK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA SOUTH OF THE SAHARA; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DEVELOPING COUNTRY; DISEASE ASSOCIATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LUNG TUBERCULOSIS; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; COMBINATION DRUG THERAPY; FEMALE; HIV INFECTIONS; MALE; META ANALYSIS; MICROBIOLOGY; SOCIOECONOMICS; TUBERCULOSIS, PULMONARY; VIROLOGY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; SOCIOECONOMIC FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84911871898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111209     Document Type: Article

References (55)

1. World Health Organisation (2013) Global Tuberculosis Report 2013. Geneva, Switzerland. Available: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf. Accessed 2014 Jan 16.
2. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, et al. (2010) Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 10: 489-498.
3. Suthar AB, Lawn SD, Del Amo J, Getahun H, Dye C, et al. (2012) Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis. PLoS Med 9: e1001270.
4. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD (2012) Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community. PLoS One 7: e34156.
5. World Health Organisation(2010) Tuberculosis Country Profiles. Available: http://www.who.int/tb/country/data/download/en/index.html. Accessed 2012 May 10.
6. UNAIDS (2010) HIV estimates with uncertainity bounds 2009. Availble: http://www.unaids.org/globalreport/documents/HIV-Estimates-GR2010-2009-en. xls. Accessed 2012 May 10.
7. UNAIDS (2012) Adult (15-49) HIV prevalence percent by country, 1990-2007. Available: data.unaids.org/pub/20080813-gr08-prev1549-1990-2007. Accessed 2012 May 10.
8. World Bank (2012) World Bank Analytical Classifications 1987-2010. Available: http://data.worldbank.org/about/country-classifications. Accessed 2012 Jul 1.
9. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, et al. (n.d.) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Available: http://www.medicine.mcgill.ca/rtamblyn/Readings/The%20Newcastle%20-%20 Scale%20for%20assessing%20the%20quality%20of%20nonrandomised%20 studies%20in%20meta-analyses.pdf. Accessed 2012 May 11.
10. Hermans S, van Leth F, Manabe Y, Hoepelman A, Lange J, et al. (2012) Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. HIV Med.
11. Worodria W, Massinga-Loembe M, Mayanja-Kizza H, Namaganda J, Kambugu A, et al. (2011) Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol 2011: 758350.
12. Taarnhoj GA, Engsig FN, Ravn P, Johansen IS, Larsen CS, et al. (2011) Incidence, risk factors and mortality of tuberculosis in Danish HIV patients 1995-2007. BMC Pulm Med 11: 26.
13. Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, et al. (2011) Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr 57: 305-310.
14. Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodriguez M (2011) Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr 57: 311-318.
15. Martin-Echevarria E, Rodriguez-Zapata M, Torralba M, Fernandez JM, Moreno A, et al. (2011) Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count. Int J Tuberc Lung Dis 15: 1347-1352.
16. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, et al. (2011) Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS 25: 1505-1513.
17. Kabali C, von Reyn CF, Brooks DR, Waddell R, Mtei L, et al. (2011) Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. Int J Tuberc Lung Dis 15: 1515-1521, i.
18. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, et al. (2011) Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 204: 893-901.
19. Van Rie A, Westreich D, Sanne I (2011) Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 56: 349-355.
20. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, et al. (2010) Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 24: 1323-1328.
21. Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, et al. (2010) Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS 24: 1849-1855.
22. Houlihan CF, Mutevedzi PC, Lessells RJ, Cooke GS, Tanser FC, et al. (2010) The tuberculosis challenge in a rural South African HIV programme. BMC Infect Dis 10: 23.
23. Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, et al. (2010) Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One 5: e10527.
24. Hanrahan CF, Golub JE, Mohapi L, Tshabangu N, Modisenyane T, et al. (2010) Body mass index and risk of tuberculosis and death. AIDS 24: 1501-1508.
25. Dembele M, Saleri N, Carvalho AC, Saouadogo T, Hien AD, et al. (2010) Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. IntJ Tuberc Lung Dis 14: 318-323.
26. Abgrall S, Del Giudice P, Melica G, Costagliola D (2010) HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. AIDS 24: 763-771.
27. Zhou J, Elliott J, Li PC, Lim PL, Kiertiburanakul S, et al. (2009) Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis 9: 46.
28. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R (2009) Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23: 1717-1725.
29. Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, et al. (2009) Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 23: 2507-2515.
30. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, et al. (2009) Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 23: 631-636.
31. Etard JF, Diouf A, De Beaudrap P, Akoi K, Ngom-Gueye NF, et al. (2009) Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. Open AIDS J 3: 63-70.
32. Moreno S, Jarrin I, Iribarren JA, Perez-Elias MJ, Viciana P, et al. (2008) Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. IntJ Tuberc Lung Dis 12: 1393-1400.
33. Lannoy LH, Cortez-Escalante JJ, Evangelista Mdo S, Romero GA (2008) Tuberculosis incidence and risk factors among patients living with HIV/AIDS in public health service institutions in Brasilia, Federal District. Rev Soc Bras Med Trop 41: 549-555.
34. Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, et al. (2008) Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 22: 2527-2533.
35. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, et al. (2007) Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21: 713-719.
36. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, et al. (2007) Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21: 2483-2491.
37. Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, et al. (2007) Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One 2: e826.
38. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. (2007) The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 21: 1441-1448.
39. Lawn SD, Myer L, Bekker LG, Wood R (2006) Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20: 1605-1612.
40. Jerene D, Naess A, Lindtjorn B (2006) Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res Ther 3: 10.
41. Bonnet MM, Pinoges LL, Varaine FF, Oberhauser BB, O'Brien DD, et al. (2006) Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 20: 1275-1279.
42. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, et al. (2005) Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. AmJ Respir Crit Care Med 172: 123-127.
43. Lawn SD, Badri M, Wood R (2005) Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19: 2109-2116.
44. Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, et al. (2005) Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 41: 1772-1782.
45. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, et al. (2003) Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther 8: 385-393.
46. Hung CC, Hsiao CF (2003) Recurrence of tuberculosis in HIV-1-infected adults treated after rifamycin-based treatment and highly active antiretroviral therapy. J Acquir Immune Defic Syndr 34: 437-439.
47. Badri M, Wilson D, Wood R (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359: 2059-2064.
48. Jones JL, Hanson DL, Dworkin MS, DeCock KM (2000) HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 4: 1026-1031.
49. Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, et al. (2007) Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 45: 1518-1521.
50. Rajasekaran S, Raja K, Jeyaseelan L, Vijila S, Priya K, et al. (2009) PostHAART tuberculosis in adults and adolescents with HIV in India: Incidence, clinical and immunological profile. Indian Journal of Tuberculosis 69-76.
51. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M (2009) Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 87: 683-691.
52. Lawn SD, Wood R (2011) Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 204 Suppl 4: S1159-1167.
53. Laureillard D, Marcy O, Madec Y, Chea S, Chan S, et al. (2013) Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 27: 2577-2586.
54. Manabe YC, Breen R, Perti T, Girardi E, Sterling TR (2009) Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 199: 437-444.
55. Middelkoop K, Bekker LG, Shashkina E, Kreiswirth B, Wood R (2012) Retreatment tuberculosis in a South African community: the role of re-infection, HIV and antiretroviral treatment. Int J Tuberc Lung Dis 16: 1510-1516.